Company news

Imagion Biosystems Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Imagion Announces New CEO

June 18, 2023

Results of Non-renounceable Entitlement Offer

April 18, 2023

Imagion Funding Update

March 6, 2023

Non-renounceable Entitlement Offer

March 6, 2023

Imagion Secures Growth Funding

March 6, 2023

Appendix 4E

February 27, 2023

Company Update - Phase 1 Study Independent Review

February 5, 2023

Positive clinical data reported at breast cancer symposium

December 7, 2022

2021 R&D Tax Refund

October 25, 2022

Prostate cancer research update

September 27, 2022

First-in-human Study Progress Update

March 16, 2022

Full Year Results Release

February 24, 2022

Half-year results release

August 17, 2021

2020 R&D Tax Refund

May 31, 2021

First-in-human study update - First patient enrolled

May 26, 2021

Appendix 4C - quarterly

April 29, 2021

IBX raises $6M in placement

November 23, 2020

Appendix 4C & Quarterly Activity Report

October 27, 2020

Imagion announces HREC approval for Phase I study

October 6, 2020

Appendix 4D and Half Year Results H1 2020

August 25, 2020

IBX raises $5M in oversubscribed placement

July 29, 2020

Imagion establishes collaboration with Siemens Healthineers

May 19, 2020

Appendix 4C - Quarterly

April 29, 2020

Second Supplementary Prospectus

April 28, 2020

Imagion Updates Capital Raise to $2.5 Million

April 28, 2020

Supplementary Prospectus

April 22, 2020

2019 R&D Tax Refund

April 8, 2020

Renounceable Rights Issue Prospectus

March 25, 2020

Pro-Rata Renounceable Rights Issue

March 24, 2020

Trading halt

March 22, 2020

IBX General Investor Presentation - March 2020

March 1, 2020

Appendix 4E and 2019 Full Year Results

February 27, 2020

Business Update - Manufacturing commences

February 25, 2020

Response to ASX price query

December 31, 2019

Completion of Renounceable Rights Issue

November 21, 2019

Pro-Rata Renounceable Rights Issue - Amended Timetable

October 28, 2019

Investor Presentation

September 8, 2019

Appendix 4D and Half Year Report

August 29, 2019

Imagion Biosystems receives A$2 million in R&D tax incentive

July 24, 2019

FDA Breakthrough Device Designation

July 18, 2019

Imagion Biosystems successfully completes toxicology study

May 22, 2019

Imagion Biosystems receives R&D Advanced Overseas Finding

May 13, 2019

IBX receives order related to cancer treatment

April 10, 2019

IBX receives US patent related to treatment of disease

March 11, 2019

FY2018 Appendix 4E and Preliminary Report

February 28, 2019

Imagion Biosystems Raises $4.3M Via Rights Issue

November 18, 2018

Despatch of Rights Issue Offer Documents

October 3, 2018

Rights Issue Offer Document

September 23, 2018

Market Announcement - Reinstatement to official quotation

September 20, 2018

Pro-Rata Non-Renounceable Rights Issue

September 19, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 28 decks. Every deck is listed under its year.